Charles River Laboratories International (CRL) Partners With Magellan As Valuation Questions Linger

Charles River Laboratories International (CRL) drew fresh investor attention after announcing a collaboration with Magellan Stem Cells focused on stem cell therapies and regenerative medicine, supported by biologics quality control and cGMP viral testing. For context, Charles River Laboratories International has seen strong momentum build through 2026, with the share price at US$344.87 after a 1-day share price return of 9.33%, a 30-day share price return of 23.60% and a year-to-date share...